Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nafcillin Sodium

FDA-approved product (capsule, oral), marketed as Nafcillin Sodium, Nallpen, Nallpen In Plastic Container and 2 more.

Registered studies
19
Lab records
7
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nafcillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF06

Repurposing investigation

Nafcillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA74.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 4 of 7 lab records
Open Nafcillin Sodium in ChEMBL Registered studies below
Show the 7 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nafcillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

    NCT07376889 · start 2026-02-01

    Registered record
    Registry ID
    NCT07376889
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-01
    Enrolment
    2,096

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    PhasePhase 4
    Registry statusRecruiting

  • Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

    NCT07148960 · start 2025-09-15

    Registered record
    Registry ID
    NCT07148960
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Early Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2025-09-15
    Completion
    2027-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionEarly Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?

    NCT05001750 · start 2021-06-14

    Registered record
    Registry ID
    NCT05001750
    Conditions
    Subarachnoid Hemorrhage; Intracerebral Hemorrhage; Ventriculitis, Cerebral; Hydrocephalus
    Interventions
    Long term (continuous) prophylactic antibiotics; 24 hours antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-06-14
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Intracerebral Hemorrhage; Ventriculitis, Cerebral; Hydrocephalus
    InterventionLong term (continuous) prophylactic antibiotics; 24 hours antibiotics
    PhasePhase 1
    Registry statusRecruiting

  • DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

    NCT04775953 · start 2021-04-22

    Registered record
    Registry ID
    NCT04775953
    Conditions
    Staphylococcal Bacteraemia
    Interventions
    Cefazolin; Dalbavancin; Daptomycin; Nafcillin; Oxacillin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-04-22
    Completion
    2023-12-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Bacteraemia
    InterventionCefazolin; Dalbavancin; Daptomycin; Nafcillin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

    NCT03426761 · start 2018-01-25

    Registered record
    Registry ID
    NCT03426761
    Conditions
    Bone Infection; Osteomyelitis; Septic Arthritis; Joint Infection; Prosthetic Joint Infection
    Interventions
    Dalbavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2022-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Infection; Osteomyelitis; Septic Arthritis; Joint Infection +1 more
    InterventionDalbavancin; Vancomycin
    PhasePhase 4
    Registry statusCompleted

  • Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

    NCT02344511 · start 2016-03

    Registered record
    Registry ID
    NCT02344511
    Conditions
    Osteomyelitis
    Interventions
    Dalbavancin; cefazolin, nafcillin, oxacillin or vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-03
    Completion
    2019-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    InterventionDalbavancin; cefazolin, nafcillin, oxacillin or vancomycin
    PhasePhase 3
    Registry statusWithdrawn

  • A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

    NCT02208063 · start 2014-12

    Registered record
    Registry ID
    NCT02208063
    Conditions
    Bacteremia
    Interventions
    Telavancin; Vancomycin; Daptomycin; Synthetic penicillin; Cefazolin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-12
    Completion
    2018-04-12
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionTelavancin; Vancomycin; Daptomycin; Synthetic penicillin +1 more
    PhasePhase 3
    Registry statusTerminated

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)

    NCT01922011 · start 2013-09-13

    Registered record
    Registry ID
    NCT01922011
    Conditions
    Acute Hematogenous Osteomyelitis
    Interventions
    Daptomycin; Vancomycin (or equivalent); Nafcillin (or equivalent)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-13
    Completion
    2016-12-20
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Hematogenous Osteomyelitis
    InterventionDaptomycin; Vancomycin (or equivalent); Nafcillin (or equivalent)
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

    NCT01756924 · start 2012-12

    Registered record
    Registry ID
    NCT01756924
    Conditions
    Prosthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers
    Interventions
    CEM-102; IV or Oral standard of care antibiotics; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-12
    Completion
    2014-07
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers
    InterventionCEM-102; IV or Oral standard of care antibiotics; Rifampin
    PhasePhase 2
    Registry statusTerminated

  • Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

    NCT01431326 · start 2011-11

    Registered record
    Registry ID
    NCT01431326
    Conditions
    Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
    Interventions
    The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2019-11
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 more
    InterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusCompleted

  • Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

    NCT01191840 · start 2011-02

    Registered record
    Registry ID
    NCT01191840
    Conditions
    Bacteremia
    Interventions
    Vancomycin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-03-04
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionVancomycin; Vancomycin
    PhasePhase 2
    Registry statusCompleted

  • Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

    NCT01104662 · start 2010-04-19

    Registered record
    Registry ID
    NCT01104662
    Conditions
    Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
    Interventions
    Vancomycin; Daptomycin; Semi-Synthetic Penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-04-19
    Completion
    2012-06-12
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
    InterventionVancomycin; Daptomycin; Semi-Synthetic Penicillin
    PhasePhase 4
    Registry statusTerminated

  • Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

    NCT00711802 · start 2008-07-23

    Registered record
    Registry ID
    NCT00711802
    Conditions
    Skin Diseases, Infectious
    Interventions
    Daptomycin; Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07-23
    Completion
    2013-10-11
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionDaptomycin; Standard of Care (SOC)
    PhasePhase 4
    Registry statusCompleted

  • Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

    NCT00428844 · start 2007-06-26

    Registered record
    Registry ID
    NCT00428844
    Conditions
    Osteomyelitis
    Interventions
    daptomycin; daptomycin; vancomycin; teicoplanin; nafcillin; oxacillin; flucloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06-26
    Completion
    2010-06-23
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventiondaptomycin; daptomycin; vancomycin; teicoplanin +3 more
    PhasePhase 2
    Registry statusCompleted